RusnanoMedInvest specializes in investing in the development of innovative pharmaceutical technologies and products in Russia and worldwide.
We are interested in investment opportunities in promising new developments in the field of pharmaceuticals and medical equipment;
Our investment strategy and focus centers primarily around projects at the later stages of development, in particular compounds or products that have proven, market-relevant differentiated therapeutic efficacy, tolerability or safety in phase 2 or later or otherwise demonstrate game-changing potential with respect to patient welfare or healthcare economics.
Our portfolio companies:
Marinus Pharmaceuticals, Inc.(Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which will become effective prior to the open of U.S. markets Monday, December 18, 2017.
13 December 2017
30 November 2017
28 November 2017